Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01204996 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors
A Phase 1 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT01204996: Completed Phase 1 study, sponsored by Centocor.
NCT01204996 is a Phase 1 study that has completed, run by Centocor. The registered enrollment target is 53 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01204996, a Phase 1 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and dose regimen of CNTO 888 when administered to patients with solid tumors in combination with 4 standard of care chemotherapy regimens.
Interventions
- DRUG CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection
- DRUG CNTO888 + gemcitabine
- DRUG CNTO888 + Paclitaxel and carboplatin
- DRUG CNTO888 + docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
What the finished NCT01204996 record still lists
NCT01204996 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% lower).
The record links to 0 conditions, and to 4 interventions - of which CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection is the first listed.
NCT01204996 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01204996 about?
NCT01204996 is a clinical study titled "A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors". The purpose of this study is to evaluate the safety and dose regimen of CNTO 888 when administered to patients with solid tumors in combination with 4 standard of care chemotherapy regimens.
What is the current status of trial NCT01204996?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2010-05. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01204996?
The interventions under investigation include: CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection (DRUG), CNTO888 + gemcitabine (DRUG), CNTO888 + Paclitaxel and carboplatin (DRUG), CNTO888 + docetaxel (DRUG).
Who is sponsoring clinical trial NCT01204996?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01204996's enrollment target sits among peer trials
53 948th of 2000 higher than 1,045 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia